Gyre Therapeutics, Inc. GYRE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.5M+1.2% | $37.07M-8.2% | $40.4M+10.7% | $36.49M+143% | $15.05M+27.4% | ||
| $12.31M-19.9% | $15.36M-21.8% | $19.65M+9.9% | $17.87M+20.4% | $14.85M-0.1% | ||
| $104.35M+2.6% | $101.73M+12.7% | $90.25M+7.6% | $83.86M+7.7% | $77.85M+6.4% | ||
| $39.24M+9.7% | $35.76M+12.0% | $31.93M+8.4% | $29.46M+12.3% | $26.23M+12.6% | ||
| $91.73M-10.4% | $102.37M+3.8% | $98.58M+8.0% | $91.29M+33.4% | $68.45M+5.7% | ||
| $23.57M-0.1% | $23.6M0.0% | $23.61M+0.9% | $23.4M-0.5% | $23.52M-1.5% | ||
| $4.63M-2.1% | $4.73M-2.5% | $4.85M-2.3% | $4.96M-2.4% | $5.08M+1,762% | ||
| $162.02M-2.5% | $166.13M+4.2% | $159.38M+4.4% | $152.65M+17.6% | $129.79M+3.5% | ||
| $265K+114% | $124K-77.7% | $556K+683% | $71K-41.8% | $122K+13.0% | ||
| $840K+5,900% | $14K-75.9% | $58K— | $0-100% | $28K-54.1% | ||
| $19.79M+8.2% | $18.29M+14.9% | $15.91M-6.0% | $16.92M-10.9% | $18.99M-2.7% | ||
| $25.03M+4.9% | $23.85M+8.6% | $21.97M-5.3% | $23.2M-9.0% | $25.49M-5.6% | ||
| $91K0.0% | $91K0.0% | $91K0.0% | $91K+4.6% | $87K+1.2% | ||
| -$77.67M-13.5% | -$68.43M-2.6% | -$66.7M+5.1% | -$70.31M+0.6% | -$70.76M+3.7% | ||
| $101.31M-4.5% | $106.03M+4.0% | $101.92M+10.8% | $92.03M+35.1% | $68.12M+7.6% | ||
| $162.02M-2.5% | $166.13M+4.2% | $159.38M+4.4% | $152.65M+17.6% | $129.79M+3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s total assets?
- Gyre Therapeutics, Inc. (GYRE) holds $162.0M in total assets, up 24.8% year over year.
- How much debt does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. carries $823.0K in total debt against $101.3M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. holds $37.5M in cash and equivalents.
- Can Gyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.64 — current assets exceed current liabilities.
- Where does Gyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
